With a plethora of FDA-approved regimens for treatment of multiple myeloma, a personalized approach is the key to obtaining deeper and more durable responses for both newly diagnosed disease and in the relapsed setting. Some of the newer agents are oral medications adding to the patient’s quality of life. I’m Dr. Peter Salgo, here to tell you about an upcoming Specialty Pharmacy Times Practice Pearls discussion that aims to address the process of properly dispensing these oral agents.
In this Specialty Pharmacy Times Practice Pearls, I am going to be joined by a panel of experts from various backgrounds in the medical community. We will discuss the role of the Specialty Pharmacies and best practice with dispensing these new oral oncolytics. What are the concerns with obtaining prior authorization? What are the causes of time delays to dispensing the medications? All of these questions will be addressed by keynote speakers who have extensive, personal experience in this setting.
With the multiple steps involved, with obtaining prior authorization and limited number of pharmacies allowed to fill these specific agents, it’s important to have a complete understanding of process to get the medications in the patients’ hands quickly to ensure therapy is not impacted. Don’t miss this opportunity to be informed on the latest in identifying the best practices for dispensing oral oncolytics for myeloma. With that in mind, we hope you’ll join us for this cutting-edge Specialty Pharmacy Times Practice Pearls — see you there.